We have utilized this composite-based endpoint and associated guidelines, among other measures, in the evaluation of our Phase 2 results.
Improvement in chronic low back pain. At 12 months, a responder analysis showed that there was clear separation between both treatment groups and both control groups at every decile increase in response beyond the MICD of 30% reduction in pain from baseline. In line with guidance from KOLs and from payers, a responder analysis was performed targeting at least 50% reduction in pain from baseline. At both 6 and 12 months, a reduction in pain from baseline of 50% or more, without any additional intervention, was seen in 59.3% of the MPC-06-ID group, 44.8% of the 18 million MPC group, 18.8% of the saline group, and 15.8% of the HA group, as measured by visual analog scale, or VAS (p = 0.006 across all four groups, p=0.023 for 6 million MPC against saline and p=0.006 against HA). Statistical significance denotes the mathematical likelihood that the results observed are real and not due to chance.
- Forums
- ASX - By Stock
- MSB
- Back pain read out - what are your thoughts?
Back pain read out - what are your thoughts?, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43856 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 66000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 43856 | 1.105 |
10 | 148573 | 1.100 |
3 | 95461 | 1.095 |
6 | 150805 | 1.090 |
4 | 77833 | 1.085 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 66000 | 1 |
1.115 | 89808 | 3 |
1.120 | 510896 | 9 |
1.125 | 100845 | 7 |
1.130 | 142733 | 8 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |